GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of
cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company,
effective 1 January, 2021.
Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and Diagnostics industry across NASDAQ, Euronext and AIM-listed public companies, as well as private companies in the U.S., UK and Europe. He is a strategic and commercially focused leader with significant experience at the board level across large and small companies, with specific focus in recent years on diagnostic companies in the small to midcap space.
Bill holds a Bachelor’s of Science and Masters in International Business and served as Worldwide President of Becton Dickinson’s Biosciences business and was Becton Dickinson’s Corporate Executive Officer for Strategy and Corporate Development. Bill currently also serves as Chairman at OpGen Inc, Omega Diagnostics Group PLC and CytoSMART Technologies, and had been the Chairman
of the Supervisory Board of Curetis until its combination with OpGen. He also currently sits on the Board of Paramit Corp. in Morgan Hill, California.
Bill has substantial corporate and commercial expertise and experience including fundraising, IPOs, mergers, acquisitions and divestment, with over $1 billion of fundraising and M&A transactions accomplished in the UK, Europe and the U.S. He is active with his alma mater, Cornell University, mentoring life sciences startups there as a Senior Executive in Residence, and serves as an advisor to Altaris Capital Partners, a large U.S.-based healthcare private equity fund.
Matthew Walls, Chief Executive Officer, said: “We are delighted to welcome Bill to the Company and Board. Bill brings an international and U.S. focus to strengthen the Board and joins us at an exciting time as we prepare to execute the next steps in the Company’s global growth strategy.”
GENinCode UK Limited
Tel +44 (0)7887 501998
Original Source: www.newswire.com